Canagliflozin (Cana), besides being used to treat type 2 diabetes mellitus by inhibiting sodium-glucose co-transporter-2 (SGLT2), Plosker et al.28 have been shown to improve kidney function in diabetic nephropathic patients and liver function in type 2 diabetes patients29,30. Cana showed a mitigation effect on APAP-induced nephrotoxicity in the current investigation, as indicated by the reduction of well-known kidney injury parameters: KIM-1, NGAL, creatinine, and BUN levels. The gene discussed is HAVCR1; the disease is diabetes mellitus.